The future of antiphospholipid antibody testing

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 4, 2012, Pages 412-419

  De Groot, Philip G ^a   Urbanus, Rolf T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

anticardiolipin antibodies; antiphospholipid antibodies; glycoprotein I; lupus anticoagulant

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL FEATURE; HUMAN; IMMUNOASSAY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; STANDARDIZATION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; PREGNANCY;

EID: 84861348168     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1304715     Document Type: Article

References (74)

1. Miyakis S, Lockshin MD, Atsumi D., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
2. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood: 2009; 114 10 2020 2030
3. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA: 2006; 296 15 1858 1866 (Pubitemid 44596195)
4. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE.; UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol: 2002; 119 2 364 369 (Pubitemid 35365483)
5. Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin Thromb Hemost: 2008; 34 4 340 346
6. Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A.; Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-glycoprotein I activity. Thromb Res: 2007; 120 1 127 133 (Pubitemid 46628706)
7. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol: 2002; 118 4 548 557 (Pubitemid 44698512)
8. Favaloro EJ, Wong RC, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost: 2005; 31 1 73 84 (Pubitemid 40262140)
9. Pengo V, Tripodi A, Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood: 2003; 101 5 1827 1832 (Pubitemid 36237580)
11. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood: 2003; 102 8 2717 2723 (Pubitemid 37248837)
12. Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost: 2008; 6 2 399 401
13. Hlatky MA, Greenland P, Arnett DK., et al. American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation: 2009; 119 17 2408 2416
14. Urbanus RT, de Groot PG. Antiphospholipid antibodieswe are not quite there yet. Blood Rev: 2011; 25 2 97 106
15. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol: 2002; 119 4 1005 1010 (Pubitemid 35463826)
16. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost: 2006; 4 1 44 49
17. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol: 2009; 8 11 998 1005
18. Levine SR, Brey RL, Tilley BC., et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA: 2004; 291 5 576 584 (Pubitemid 38500311)
19. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med: 2011; 270 2 110 122
20. Reddel SW, Wang YX, Krilis SA. Anti-beta2-glycoprotein I autoantibodies require an antigen density threshold, consistent with divalent binding. Lupus: 2003; 12 1 37 45 (Pubitemid 36172661)
21. de Laat B, Derksen RHWM, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-2-glycoprotein I antibodies recognize domain I of 2-glycoprotein I only after a conformational change. Blood: 2006; 107 5 1916 1924 (Pubitemid 43289372)
22. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A: 1998; 95 26 15542 15546 (Pubitemid 29018735)
23. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun: 2000; 15 2 91 96
24. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood: 2005; 105 4 1540 1545 (Pubitemid 40223671)
25. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum: 2007; 56 1 280 290 (Pubitemid 46106202)
26. De Laat B, Derksen RH, Reber G., et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost: 2011; 9 1 149 153
27. Neville C, Rauch J, Kassis J., et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost: 2009; 101 1 100 107
28. Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep: 2011; 13 1 59 69
29. Favaloro EJ, Bonar R, Sioufi J., et al. RCPA QAP in Haematology. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Haematology. Semin Thromb Hemost: 2005; 31 49 58 (Pubitemid 40262137)
30. Erkan D, Harrison MJ, Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum: 2007; 56 7 2382 2391 (Pubitemid 47173586)
31. van Goor MP, Alblas CL, Leebeek FW, Koudstaal PJ, Dippel DW. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand: 2004; 109 6 410 415 (Pubitemid 38698179)
32. Pengo V. Antiphospholipid syndrome: interpretation of laboratory data. J Thromb Haemost: 2011; 9 2 402 403
33. Ruffatti A, Tonello M, Del Ross T., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost: 2006; 96 3 337 341 (Pubitemid 44377818)
34. Pengo V, Ruffatti A, Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost: 2010; 8 2 237 242
35. Pengo V, Ruffatti A, Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood: 2011; 118 17 4714 4718
36. Shoenfeld Y, Krause I, Kvapil F., et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol: 2003; 23 5 377 383 (Pubitemid 37083192)
37. de Laat B, van Os G, Ninivaggi M., et al. Anti-domain I antibodies have a prothrombotic character on coagulation by inhibiting the anticoagulant effect of beta2-glycoprotein. J Throm Haemost: 2010; 9 02 O-TU-93 (abstract)
38. Simmelink MJA, Derksen RHWM, Arnout J, De Groot PG. A simple method to discriminate between 2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost: 2003; 1 4 740 747
39. de Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood: 2004; 104 12 3598 3602 (Pubitemid 39564433)
40. De Laat B, Derksen RH, Reber G., et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost: 2011; 9 1 149 153
41. Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood: 1999; 94 11 3814 3819
42. Rand JH, Wu XX, Andree HA., et al. Pregnancy loss in the antiphospholipid-antibody syndromea possible thrombogenic mechanism. N Engl J Med: 1997; 337 3 154 160 (Pubitemid 27306286)
43. Rand JH, Wu X-X, Lapinski R., et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood: 2004; 104 9 2783 2790 (Pubitemid 39434962)
44. Hunt BJ, Wu XX, de Laat B, Arslan AA, Stuart-Smith S, Rand JH. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol: 2011; 205 5 485, e17-e23
45. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of 2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood: 2007; 109 4 1490 1494 (Pubitemid 46239580)
46. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost: 1991; 66 6 629 632
47. Simmelink MJA, Derksen RHWM, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost: 2003; 1 4 740 747
48. Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood: 1996; 88 11 4173 4182 (Pubitemid 26399163)
49. Atsumi T, Ieko M, Bertolaccini ML., et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum: 2000; 43 9 1982 1993
50. Devreese KMJ, Hoylaerts MF. Autoantibodies against prothrombin and prothrombin phosphatidylserine complex: a diagnostic tool for the antiphospholipid syndrome? J Thromb Haemost: 2011; 9 02 P-MO-354
51. Shen YM, Lee R, Frenkel E, Sarode R. IgA antiphospholipid antibodies are an independent risk factor for thromboses. Lupus: 2008; 17 11 996 1003
52. Mehrani T, Petri M. Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol: 2011; 38 1 64 68
53. Sweiss NJ, Bo R, Kapadia R., et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS ONE: 2010; 5 8 e12280
54. Toschi V, Motta A, Castelli C., et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. Haemostasis: 1993; 23 5 275 283 (Pubitemid 24051062)
55. Mcintyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun: 2000; 15 2 185 193
56. Sanmarco M, Gayet S, Alessi MC., et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost: 2007; 97 6 949 954 (Pubitemid 46939208)
57. Rolla R, Vidali M, Serino R, Pergolini P, Albano E, Bellomo G. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. Clin Exp Immunol: 2007; 149 1 63 69 (Pubitemid 46897111)
58. Alessandri C, Sorice M, Bombardieri M., et al. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res Ther: 2006; 8 6 R180
59. Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev: 2008; 7 7 558 566
60. Ao W, Zheng H, Chen XW, Shen Y, Yang CD. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int: 2011; 31 7 865 869
61. Dieud M, Correa JA, Neville C., et al. Association of autoantibodies to heat-shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies. Arthritis Rheum: 2011; 63 8 2416 2424
62. Hughes GRV, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol: 1986; 13 3 486 489
63. Agar C, van Os GM, Mörgelin M., et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood: 2010; 116 8 1336 1343
64. Biasiolo A, Rampazzo P, Brocco T, Barbero F, Rosato A, Pengo V. [Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus: 1999; 8 2 121 126 (Pubitemid 29103598)
65. 2-glycoprotein I: a novel component of innate immunity. Blood: 2011; 117 25 6939 6947
66. Passam FH, Rahgozar S, Qi M., et al. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood: 2010; 116 11 1995 1997
67. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modifications of beta2-glycoprotein I. J. Thromb Haemost: 2011; 9 01 275 282
68. Ioannou Y, Zhang JY, Qi M., et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen 2-glycoprotein I. Arthritis Rheum: 2011; 63 9 2774 2782
69. Holers VM, Girardi G, Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med: 2002; 195 2 211 220 (Pubitemid 34461265)
70. Girardi G, Berman J, Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest: 2003; 112 11 1644 1654 (Pubitemid 38063722)
71. Stewart MW, Etches WS, Gordon PA. Antiphospholipid antibody-dependent C5b-9 formation. Br J Haematol: 1997; 96 3 451 457 (Pubitemid 27087226)
72. 2-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood: 2011; 118 10 2774 2783
73. 2- glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood: 2011; 117 12 3453 3459
74. Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev: 2011; 10 10 609 616